![Phase II study of carboplatin/nab-paclitaxel/atezolizumab combination therapy for advanced nonsquamous non–small cell lung cancer patients with impaired renal function: RESTART trial | BMC Cancer | Full Text Phase II study of carboplatin/nab-paclitaxel/atezolizumab combination therapy for advanced nonsquamous non–small cell lung cancer patients with impaired renal function: RESTART trial | BMC Cancer | Full Text](https://media.springernature.com/m685/springer-static/image/art%3A10.1186%2Fs12885-022-10056-x/MediaObjects/12885_2022_10056_Fig1_HTML.png)
Phase II study of carboplatin/nab-paclitaxel/atezolizumab combination therapy for advanced nonsquamous non–small cell lung cancer patients with impaired renal function: RESTART trial | BMC Cancer | Full Text
![Erstlinientherapie beim fortgeschrittenem NSCLC: Nab-Paclitaxel - das innovative und effektivere Taxan Erstlinientherapie beim fortgeschrittenem NSCLC: Nab-Paclitaxel - das innovative und effektivere Taxan](https://www.journalonko.de/app/webroot/js/kcfinder/upload/images/news/2015_8/Celg.png)
Erstlinientherapie beim fortgeschrittenem NSCLC: Nab-Paclitaxel - das innovative und effektivere Taxan
![Phase 3 Trial Comparing Nanoparticle Albumin-Bound Paclitaxel With Docetaxel for Previously Treated Advanced NSCLC - ScienceDirect Phase 3 Trial Comparing Nanoparticle Albumin-Bound Paclitaxel With Docetaxel for Previously Treated Advanced NSCLC - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S1556086421021079-gr1.jpg)
Phase 3 Trial Comparing Nanoparticle Albumin-Bound Paclitaxel With Docetaxel for Previously Treated Advanced NSCLC - ScienceDirect
![Efficacy and safety of carboplatin with nab-paclitaxel versus docetaxel in older patients with squamous non-small-cell lung cancer (CAPITAL): a randomised, multicentre, open-label, phase 3 trial - The Lancet Healthy Longevity Efficacy and safety of carboplatin with nab-paclitaxel versus docetaxel in older patients with squamous non-small-cell lung cancer (CAPITAL): a randomised, multicentre, open-label, phase 3 trial - The Lancet Healthy Longevity](https://www.thelancet.com/cms/attachment/01f196d4-b974-4f21-ac03-8e7a06e0ae91/gr2.jpg)
Efficacy and safety of carboplatin with nab-paclitaxel versus docetaxel in older patients with squamous non-small-cell lung cancer (CAPITAL): a randomised, multicentre, open-label, phase 3 trial - The Lancet Healthy Longevity
![Longer OS with atezolizumab + carboplatin + nab-paclitaxel in advanced squamous NSCLC - Medical Conferences Longer OS with atezolizumab + carboplatin + nab-paclitaxel in advanced squamous NSCLC - Medical Conferences](https://conferences.medicom-publishers.com/wp-content/uploads/2019/11/Figure._Final_overall_survival_outcomes_in_intention-to-treat_population__Arm_B_vs_Arm_C_.png)
Longer OS with atezolizumab + carboplatin + nab-paclitaxel in advanced squamous NSCLC - Medical Conferences
![Atezolizumab plus carboplatin and nab‐paclitaxel versus carboplatin and nab‐ paclitaxel as treatments for Chinese, treatment‐naïve, stage IV, non‐squamous, non‐small‐cell lung cancer patients: A retrospective analysis - Chen - 2022 - Pharmacology Research & Atezolizumab plus carboplatin and nab‐paclitaxel versus carboplatin and nab‐ paclitaxel as treatments for Chinese, treatment‐naïve, stage IV, non‐squamous, non‐small‐cell lung cancer patients: A retrospective analysis - Chen - 2022 - Pharmacology Research &](https://bpspubs.onlinelibrary.wiley.com/cms/asset/d342d70b-7f77-4c33-be46-61afc0039b6e/prp2941-toc-0001-m.jpg?trick=1702103133722)
Atezolizumab plus carboplatin and nab‐paclitaxel versus carboplatin and nab‐ paclitaxel as treatments for Chinese, treatment‐naïve, stage IV, non‐squamous, non‐small‐cell lung cancer patients: A retrospective analysis - Chen - 2022 - Pharmacology Research &
![NSCLC | NSCLC: Patienten profitieren von nab-Paclitaxel auch in der Erhaltungstherapie | springermedizin.de NSCLC | NSCLC: Patienten profitieren von nab-Paclitaxel auch in der Erhaltungstherapie | springermedizin.de](https://media.springernature.com/lw400/springer-static/cover/journal/15015/19/7.jpg?as=jpg)
NSCLC | NSCLC: Patienten profitieren von nab-Paclitaxel auch in der Erhaltungstherapie | springermedizin.de
![Study flow diagram: patients with squamous cell non-small cell lung... | Download Scientific Diagram Study flow diagram: patients with squamous cell non-small cell lung... | Download Scientific Diagram](https://www.researchgate.net/publication/320523784/figure/fig1/AS:551518660239360@1508503703717/Study-flow-diagram-patients-with-squamous-cell-non-small-cell-lung-cancer-who-received.png)
Study flow diagram: patients with squamous cell non-small cell lung... | Download Scientific Diagram
![A Phase I/II Study of Necitumumab Plus Pembrolizumab, Nab-Paclitaxel, and Carboplatin for Previously Untreated Advanced Squamous Non–Small Cell Lung Cancer Study: (NEJ048A/NEXUS) - ScienceDirect A Phase I/II Study of Necitumumab Plus Pembrolizumab, Nab-Paclitaxel, and Carboplatin for Previously Untreated Advanced Squamous Non–Small Cell Lung Cancer Study: (NEJ048A/NEXUS) - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S1525730423000104-gr1.jpg)
A Phase I/II Study of Necitumumab Plus Pembrolizumab, Nab-Paclitaxel, and Carboplatin for Previously Untreated Advanced Squamous Non–Small Cell Lung Cancer Study: (NEJ048A/NEXUS) - ScienceDirect
![Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 ... Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 ...](https://www.thelancet.com/cms/attachment/8683c32a-7f62-4423-b701-e7a9d5ff815c/gr1_lrg.gif)
Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 ...
![Treatment Rationale and Design for J‐SONIC: A Randomized Study of Carboplatin Plus Nab‐paclitaxel With or Without Nintedanib for Advanced Non–Small‐cell Lung Cancer With Idiopathic Pulmonary Fibrosis | Semantic Scholar Treatment Rationale and Design for J‐SONIC: A Randomized Study of Carboplatin Plus Nab‐paclitaxel With or Without Nintedanib for Advanced Non–Small‐cell Lung Cancer With Idiopathic Pulmonary Fibrosis | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/bc34c1d3549723d36f899e9beba6dffe7842772f/2-Figure1-1.png)
Treatment Rationale and Design for J‐SONIC: A Randomized Study of Carboplatin Plus Nab‐paclitaxel With or Without Nintedanib for Advanced Non–Small‐cell Lung Cancer With Idiopathic Pulmonary Fibrosis | Semantic Scholar
![Carboplatin and nab-paclitaxel chemotherapy with or without atezolizumab as front-line management for treatment-naïve metastatic nonsquamous non-small cell lung cancer with PD-L1 staining: a retrospective study | Journal of Cancer Research and Clinical Carboplatin and nab-paclitaxel chemotherapy with or without atezolizumab as front-line management for treatment-naïve metastatic nonsquamous non-small cell lung cancer with PD-L1 staining: a retrospective study | Journal of Cancer Research and Clinical](https://media.springernature.com/m685/springer-static/image/art%3A10.1007%2Fs00432-021-03873-3/MediaObjects/432_2021_3873_Fig1_HTML.png)
Carboplatin and nab-paclitaxel chemotherapy with or without atezolizumab as front-line management for treatment-naïve metastatic nonsquamous non-small cell lung cancer with PD-L1 staining: a retrospective study | Journal of Cancer Research and Clinical
![Phase 3 Trial Comparing Nanoparticle Albumin-Bound Paclitaxel With Docetaxel for Previously Treated Advanced NSCLC - ScienceDirect Phase 3 Trial Comparing Nanoparticle Albumin-Bound Paclitaxel With Docetaxel for Previously Treated Advanced NSCLC - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S1556086421021079-gr2.jpg)
Phase 3 Trial Comparing Nanoparticle Albumin-Bound Paclitaxel With Docetaxel for Previously Treated Advanced NSCLC - ScienceDirect
![A Dose Finding Study of Weekly and Every-3-Week nab-Paclitaxel Followed by Carboplatin as First-Line Therapy in Patients with Advanced Non-small Cell Lung Cancer - ScienceDirect A Dose Finding Study of Weekly and Every-3-Week nab-Paclitaxel Followed by Carboplatin as First-Line Therapy in Patients with Advanced Non-small Cell Lung Cancer - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S1556086415305153-gr1.jpg)
A Dose Finding Study of Weekly and Every-3-Week nab-Paclitaxel Followed by Carboplatin as First-Line Therapy in Patients with Advanced Non-small Cell Lung Cancer - ScienceDirect
![Nab-Paclitaxel in combination with Cisplatin Versus Docetaxel Plus Cisplatin as First-Line Therapy in Non-small Cell Lung Cancer | Scientific Reports Nab-Paclitaxel in combination with Cisplatin Versus Docetaxel Plus Cisplatin as First-Line Therapy in Non-small Cell Lung Cancer | Scientific Reports](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41598-017-11404-9/MediaObjects/41598_2017_11404_Fig1_HTML.jpg)
Nab-Paclitaxel in combination with Cisplatin Versus Docetaxel Plus Cisplatin as First-Line Therapy in Non-small Cell Lung Cancer | Scientific Reports
![Biomedicines | Free Full-Text | Nab-Paclitaxel in the Treatment of Gastrointestinal Cancers—Improvements in Clinical Efficacy and Safety Biomedicines | Free Full-Text | Nab-Paclitaxel in the Treatment of Gastrointestinal Cancers—Improvements in Clinical Efficacy and Safety](https://www.mdpi.com/biomedicines/biomedicines-11-02000/article_deploy/html/images/biomedicines-11-02000-g001.png)
Biomedicines | Free Full-Text | Nab-Paclitaxel in the Treatment of Gastrointestinal Cancers—Improvements in Clinical Efficacy and Safety
![Frontiers | Consolidation With Pembrolizumab and Nab-Paclitaxel After Induction Platinum-Based Chemotherapy for Advanced Non-Small Cell Lung Cancer Frontiers | Consolidation With Pembrolizumab and Nab-Paclitaxel After Induction Platinum-Based Chemotherapy for Advanced Non-Small Cell Lung Cancer](https://www.frontiersin.org/files/Articles/666691/fonc-11-666691-HTML-r1/image_m/fonc-11-666691-g001.jpg)
Frontiers | Consolidation With Pembrolizumab and Nab-Paclitaxel After Induction Platinum-Based Chemotherapy for Advanced Non-Small Cell Lung Cancer
![nab-Paclitaxel + Carboplatin bei fortgeschrittenem NSCLC (kartoniertes Buch) | Schwäbischer Albverein e.V. nab-Paclitaxel + Carboplatin bei fortgeschrittenem NSCLC (kartoniertes Buch) | Schwäbischer Albverein e.V.](https://medien.umbreitkatalog.de/bildzentrale_original/978/313/241/9568.jpg)
nab-Paclitaxel + Carboplatin bei fortgeschrittenem NSCLC (kartoniertes Buch) | Schwäbischer Albverein e.V.
IMpower131: Final OS Results of Carboplatin + Nab-Paclitaxel ± Atezolizumab in Advanced Squamous NSCLC on Vimeo
![Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 ... Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 ...](https://www.thelancet.com/cms/attachment/005ee62f-ea0c-492b-b97c-18e609c87695/gr2_lrg.jpg)